<DOC>
	<DOCNO>NCT01860456</DOCNO>
	<brief_summary>Rationale The pharmacokinetics imatinib nilotinib , two BCR/Abl tyrosine-kinase inhibitor ( TKI ) , variable among patient suffer chronic myeloid leukemia ( CML ) . Transmembrane transporter may play pivotal role interindividual variability TKI disposition . Furthermore , minimum plasma concentration ( Cmin ) high 1 mg/L could associate high likelihood molecular cytogenetic response . Therefore , TIKlet study aim evaluate possible correlation among pharmacogenetics transmembrane transporter , imatinib nilotinib pharmacokinetics treatment efficacy/tolerability CML patient . 1 . PATIENTS AND METHODS 1.1 . Patients Patients affect CML enrol TIKLet study inform consent sign . The following inclusion criterion adopt : - patient sex , - age 18 80 year , - treat imatinib nilotinib , - include follow-up Divisions / Units Hematology involve project , - able give inform consent trial participation , - prove compliance schedule treatment . The administration drug allow , active pharmacological agent , dose duration treatment know . Smoking herbal product allow record . Alterations liver kidney function , body mass index &gt; 28 , alteration physicochemical exam represent exclusion criterion . 1.2 . Enrolment follow-up visit During enrolment visit , follow activity take place : - patient informed characteristic , objective , procedure study . - Patient 's consent study participation confirm sign informed consent form . - Assignment personal alphanumeric code . - Collection main data patient within individual case report form ( CRF ) . - Collection blood sample ( approximately 4 mL ) . At follow-up visit , blood sample ( approximately 4 mL ) collect therapeutic drug monitoring drug patient ' CRF update . The blood sample record send Dept . Clinical Experimental Medicine , University Pisa . 1.3 . Blood sample Each tube contain patient 's whole blood , plasma DNA use execution therapeutic monitoring pharmacogenetic analysis identify ) patient 's code b ) date execution blood withdrawal . After centrifugation blood sample , result plasma ( 1.5 mL ) collect stored eppendorf tube measurement drug concentration . During enrolment visit , aliquot whole blood ( 0.5 mL ) collect sterile eppendorf tube molecular analysis . Both sample store -20 °C maximum 2 week , send Dept . Clinical Experimental Medicine , University Pisa . 1.4 Laboratory analyse The following analysis conduct Department Clinical Experimental Medicine , University Pisa Department Pharmacology , University Bologna . Plasma concentration drug ( i.e. , imatinib metabolite , nilotinib ) measure high-performance liquid chromatography system . Values plasma concentration analyze population pharmacokinetic analysis obtain main pharmacokinetic parameter ( i.e. , clearance drug ) . Those parameter help describe quantitative manner drug disposition every patient . Furthermore , DNA extract whole blood genetic variant ( call single nucleotide polymorphism ) investigate follow gene code transmembrane transporter : ABCB1 , ABCG2 , hOCT1 , OCTN1 , OATP1A2 . Finally , response drug , term Major Molecular Response ( MMR ) Complete Cytogenetic Response ( CCyR ) , tolerability evaluate . Any possible correlation among drug disposition , pharmacogenetics treatment effect analyze .</brief_summary>
	<brief_title>TyrosIne Kinase Inhibitors Chronic Myeloid Leukemia : Efficacy Tolerability . The TIKlet Study</brief_title>
	<detailed_description>1 . Patients 1.1 . Patients CML patient include accord follow inclusion criterion : ) patient sex , b ) age 18 80 year , c ) treat imatinib nilotinib , ) include follow-up Divisions / Units Hematology involve project e ) able give inform consent trial participation , f ) prove compliance schedule treatment . Patients exclude participation study : ) age &lt; 18 &gt; 80 year b ) unable provide inform consent . The inability attend follow-up visit consider exclusion criterion study . In case , collect data use pharmacokinetic statistical analysis basis intention-to-treat criterion . The following condition note : 1. concomitant administration drug allow , provide know active ingredient , dose period administration ; 2. smoking herbal product allow report patient 's case report form ; 3. alteration liver kidney function , body mass index high 28 , alteration physicochemical exam represent exclusion criterion . 1.2 . Sample size For purpose study estimate need recruit least 206 subject per drug ( total , 412 patient ) , take account : 1. minor allele frequency study polymorphism evaluate research protocol ( i.e. , 0.3 , T allele ABCB1 c.3435C &gt; T polymorphism ) ; 2. 1:1 ratio allele C carrier patient homozygous T allele ABCB1 c.3435C &gt; T polymorphism ; 3. covariate effect drug pharmacokinetics consider significant mean difference pharmacokinetic parameter least 20 % ; 4. power study 80 % ; 5. alpha error set 0.05 . 1.3 . Enrollment Patient enrollment various participate center competitive , achievement 206 individual per drug . At first visit , TIKlet study present patient satisfy inclusion / exclusion criterion . The following activity take place : - patient informed characteristic , objective , procedure study . - Consent study participation confirm sign informed consent form . - Personal alphanumeric code assignment patient 's identification privacy . - Updating enrollment list . - Collection main data patient ( age , sex , age diagnosis , clinical chemistry test result report patient 's record combination therapy , dos duration ) within individual case report form ( CRF ) . - A blood withdrawal ( approximately 4 mL ) perform peripheral vein forearm . The time blood withdrawn register within patient 's CRF , together time elapse last administration imatinib nilotinib . For sample handle see section 2.1 . `` Blood sample handle '' . - The updated list enrol patient individual case report form send Division Hematology , Dept . Clinical Experimental Medicine , University Pisa 1.4 Follow-up visit According clinical routine participate center , follow activity perform follow-up visit : - Collection patient 's data : clinical chemistry test result , cytogenetic analysis molecular biology result ( BCR/Abl transcript level ) , concomitant therapy , adverse drug reaction . - A blood sample ( approximately 4 mL ) collect peripheral vein forearm . The time blood withdrawn register within patient 's CRF , together time elapse intake last imatinib nilotinib dose . For sample handle see section 2.1 . `` Blood sample handle '' . 2 . Laboratory analyse Laboratory analysis conduct Division Pharmacology , Department Clinical Experimental Medicine , University Pisa ( measurement drug plasma concentration , pharmacogenetic analysis ) Department Pharmacology , University Bologna ( pharmacogenetic analysis ) . 2.1 . Blood sample handle Each tube contain patient 's whole blood , plasma DNA ( see ) use execution therapeutic monitoring pharmacogenetic analysis identify ) patient 's code b ) date execution blood withdrawal . All blood sample collect lithium-heparin Vacutainer® tube , store 4 °C centrifugation . The sample centrifuge result plasma ( 1.5 mL ) collect stored tube therapeutic drug monitoring . Only enrollment visit , aliquot whole blood ( 0.5 mL ) collect sterile eppendorf molecular analysis . Both sample store -20 °C maximum 2 week , send Dept . Clinical Experimental Medicine , University Pisa . For sample storage see section 2.7 . `` Biological sample storage '' . 2.2 Measurement plasma concentration drug The measurement plasma concentration imatinib active metabolite , nilotinib conduct high-performance liquid chromatography ( HPLC ) method use commercially available kit ( Chromsystems GmbH , Munich , Germany ) Waters Breeze Alliance instrument ( Waters , USA ) . Briefly , solid-phase extraction column balance Equilibration buffer 1 2 , internal standard plasma ( 0.5 mL ) add . The column centrifuge , subsequently wash Wash buffer water HPLC . The eluate collect centrifugation , diluted water HPLC inject ( 0.025 mL ) HPLC system execution analysis . The peak area analytes interest ( imatinib active metabolite , nilotinib internal standard ) record actual concentration drug plasma obtain comparison standard calibration curve day analysis . The HPLC analysis carry weekly basis . The report analysis send Divisions / Units Hematology register patient 's medical record study CRFs . 2.3 . Pharmacokinetic analysis Plasma concentration imatinib/active metabolite nilotinib analyze trough population pharmacokinetic analysis accord nonlinear mixed-effects model approach , use NONMEM software , version 7.2 . The Xpose PsN package use check database , model diagnostic covariate testing . Former model imatinib/metabolite nilotinib 1- 2-compartment model first-order elimination parameterized term apparent drug clearance ( CL/F ) , volume distribution ( V/F ) absorption constant ( ka ) , residual error model additive , proportional mixed ( additive proportional ) error . The availability record , goodness-of-fit plot precision parameter estimate , together generalize additive modeling procedure ( GAM ) implement Xpose package , adopt model development explore correlation among covariates . In particular , age , weight , body mass index , liver ( ALT , AST ) renal function ( creatinine plasma concentration ) , albumin α1-acid glycoprotein plasma concentration result pharmacogenetic analysis consider possible covariates . A stepwise covariate model building perform forward inclusion backward exclusion . In particular , decrease objective function value ( OFV ) great 3.84 point ( i.e. , p &lt; 0.05 ) 6.63 point ( i.e. , p &lt; 0.01 ) criterion use forward inclusion backward exclusion step , respectively . The goodness final model check bootstrap analysis use PsN Xpose package calculate η-shrinkage . The area plasma concentration-time curve time zero infinity ( AUC ) terminal elimination half-life ( t1/2 ) calculate individual empirical Bayes estimate ( EBE ) final population pharmacokinetic model follow : AUC= ( Total daily dose ) / ( CL/F ) t1/2=ln ( 2 ) /kel kel imatinib elimination constant . 2.4 . Pharmacogenetic analyse The aliquot frozen whole blood employ extraction genomic DNA suitable kit ( Qiagen , Milan , Italy ) follow manufacturer 's instruction nucleic acid store -80 ° C time analysis sterile tube bear identification code patient . Single nucleotide polymorphism ( SNPs ) follow gene assay : ABCB1 , ABCG2 , hOCT1 , OCTN1 , OATP1A2 . SNPs evaluate specific kit Applied Biosystems ( Life Sciences , Milan , Italy ) ABI Prism 7900HT Sequence Detection System ( Life Sciences ) . Each analysis perform triplicate . Genotypes automatically identify software SDS ( Life Sciences ) . Frequency alleles genotype accord Hardy-Weinberg law , haplotype linkage disequilibrium analysis perform use Arlequin software package . 2.5 . Treatment effectiveness tolerability The response therapy imatinib evaluate agreement criterion recently publish adopt . In particular , result chemical , biochemical molecular analysis perform every 2 week first 3 month treatment , cytogenetic ( metaphase chromosomal band assay ) molecular analysis ( quantification BCR-ABL transcription level plasma real-time-PCR ) perform every 6 3 month , respectively , attainment complete response . The time complete cytogenetic response ( CCyR ) major molecular response ( MMR ) define length time elapse diagnosis response attainment every patient . Furthermore , treatment-associated adverse reaction ( i.e. , nausea vomiting , periorbital oedema , cramp myalgia , neutropenia , skin liver toxicity ) identify score accord Common Toxicity Criteria-NCI grading system ( version 3 ) . 2.6 . Statistical analysis The result analyze aggregate form . Parameter dispersion ( standard deviation , range ) , central index ( mean , median ) distribution ( i.e. , Kolmogorov-Smirnov test ) calculate . The appropriate statistical test ( ANOVA , Fisher test , etc . ) apply investigate possible difference group , level significance set p = 0.05 . The identification cut-off value parameter predictive efficacy / tolerability ( plasma concentration , polymorphism ) pursue trough ad hoc analysis ( receiver operating characteristic analysis , evaluation positive negative predictive value ) . 2.7 . Biological sample storage All biological sample [ whole blood ( 0.5 mL ) , plasma ( 1.5 mL ) genomic DNA ] store Division Pharmacology , Department Clinical Experimental Medicine , University Pisa . Aliquots DNA sample pharmacogenetic analysis store Department Pharmacology , University Bologna . Each sample identify individual alphanumeric code assign every patient . According protocol , patient may require destruction biological sample . 2.8 . Authorship The criterion declare ICMJE ( International Committee Medical Journal Editors ) adopt authorship definition .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Patients affect chronic myeloid leukemia Age limit : 1880 year Male female patient Treatment imatinib/nilotinib since least 3 week Optimal adherence Signed informed consent Age &lt; 18 &gt; 80 year Poor adherence Inability attend followup visit Lack sign informed consent Concomitant administration drug allow , active pharmacological agent , dose duration treatment record . Smoking consider exclusion criterium , notice record</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Chronic myeloid leukemia</keyword>
	<keyword>Imatinib</keyword>
	<keyword>Nilotinib</keyword>
	<keyword>Polymorphism , Single Nucleotide</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>ATP-Binding Cassette Transporters</keyword>
	<keyword>SLC Transporters</keyword>
	<keyword>Treatment outcome</keyword>
	<keyword>Toxicity</keyword>
</DOC>